President Alberto Fernandez today expressed his “Pride in our science and technology that is taking another step”, at the head of a new meeting of the Interministerial Table for Research, Development and Production of Vaccines, Treatments, Diagnosis and Other Technologies, made up of the Ministries of Health, Science, Technology and Innovation and Productive Development, in which they analyzed together with scientists and researchers the latest advances for the production of the national vaccine against covid-19.
Together with Minister Carla Vizzotti, Minister Daniel Filmus, and the head of Conicet, Ana Franchi; and from Fonarsec, Laura Toledo, Fernández learned about the latest advances in national vaccine production projects, including the “ARVAC-Cecilia Grierson”, Which in January 2022 will begin with the clinical phase to be able to be produced in early 2023.
During the meeting, which was also attended by the scientists who make up the four groups that are working on the production of immunization against the coronavirus, the president stressed the importance of “that we may be able to develop responses for our people” in the matter of public health and science and technology, and particularly in vaccine research and production. “It makes us enormously sovereign,” he valued.
In the same vein, Minister Vizzotti and Minister Filmus valued “the strategic gaze” of the President “to give us instruction and support” with the aim of advancing with the implementation of this commission.
“Very few countries can research and develop a vaccine, so it is a great pride,” said, in turn, the head of Conicet.
The researchers informed the President of the development status of the different projects and agreed to highlight the contribution of the State and the coordination with the private sector to “advance as quickly as possible in the availability of an Argentine vaccine against covid-19.”
In attendance were Verónica López, Paula Berguer, Julián Maggini, Eduardo Cafferata, Osvaldo Podhajcer, Daniela Hozbor, Martín Aispuro, Andrés Wigdorovitz, Juan Pablo Malito, Erika Rudi, Daiana Bianchi, Cecilia D’Alessio, Javier Santos, Guillermo Docena, Juliana Cassataro, Mirta Lorena Coria, Karina Alejandra Pasquevich, Ingrid Gisela Kaufmann and Juan Manuel Rodríguez.
The holders of the portfolios that make up the Interministerial Table visited last Tuesday the laboratories of the Institute for Biotechnological Research (IIB-Intech), dependent on Unsam, to learn about the advances of the “ARVAC-Cecilia Grierson” vaccine that they develop in a job. jointly the house of higher studies, the Conicet and the Pablo Cassará Laboratory.
Preclinical tests were shown to be effective against the virus and toxicological tests are now being completed at the Comparative Medicine Center (CMC) of the Universidad Nacional del Litoral (UNL). Once completed, the protocols of the Phase 1 trial, to be performed in humans, will be sent to the National Administration of Medicines, Food and Medical Technology (Anmat) for validation. After being approved, phase 1 is scheduled to begin during the course of January 2022.
The “ARVAC-Cecilia Grierson” is intended as a first immunization vaccine or as a booster for people who have received the full schedule of other vaccines and whose immune response begins to decline after a period of more than six months. The formula is based on recombinant proteins, a technology similar to that used in the Hepatitis B or HPV vaccine. Some of its advantages are having greater stability, avoiding conservation systems that depend on ultrafreezers, its easy distribution in national territory and being effective against new variants of covid-19.
The Head of State led 10 days ago the first meeting of this commission dedicated to promoting research, development and production of technologies for the diagnosis, treatment and control of Sars-Cov-2, as well as other health technologies.
The creation of the Interministerial Table was institutionalized on November 16, through its publication in the Official Gazette under Resolution 5/2021, with the purpose of “establishing public policies that contribute to the design of a national policy aimed at mitigating the effects of covid-19, encourage scientific and technological production and increase the capacities of the productive sector ”.